Cipla USA recalled 4,438 cartons of Phytonadione Injectable Emulsion on October 31, 2025. The product failed stability specifications, raising concerns about its safety. Consumers and healthcare providers must stop using the product immediately and seek guidance.
Failed Stability Specifications: Observed OOS results: eg results for colour index
Consumers and healthcare providers should stop using this product immediately. Contact Cipla Limited or your healthcare provider for guidance
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
This recall involves Phytonadione Injectable Emulsion, USP 10mg/mL, in 10x1 mL single-dose vials. The vials have NDC# 69097-708-31, and the cartons have NDC 69097-708-96. This product was manufactured by Cipla Ltd. in India for Cipla USA, Inc. and has a lot number PH0072404A.
The product failed stability specifications, specifically observed out-of-specification results related to color index. This implies potential degradation that may affect efficacy and safety.
No specific incidents of injury or adverse effects have been reported. However, the high hazard level indicates serious safety concerns.
Stop using the Phytonadione Injectable Emulsion immediately. Contact Cipla Limited or your healthcare provider for further guidance and assistance.
For more information, consumers can visit the FDA website or contact Cipla USA, Inc. directly at their customer service number.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.